The ion channel Potassium voltage-gated channel subfamily A member 3 (Kv1.3) is now available in relipidated format for higher purity and functionality. Potassium voltage-gated channel, member 3 Kv1.3 is a voltage-gated potassium (Kv) channel that participates in cellular processes such as neuronal excitability, epithelial electrolyte transport, smooth muscle contraction, apoptosis, cell volume regulation, and T cell stimulation. Learn more about kv1.3 [...]
NEW format available! Potassium voltage-gated channel subfamily A member 3 (Kv1.3) is now available under relipidated format6 July 2017
"Solubilisation of a strongly aggregated vaccine antigen", a research project performed for Sanofi Pasteur (France).In this case study, Synthelis was required to evaluate the capability of the cell-free technology to express the antigen of interest and avoid the formation of inclusion bodies. We were then able to demonstrate that cell-free system is a powerful alternative to circumvent precipitate issues, which come frequently across vaccine antigen [...]
Synthelis will be at the Biotech 2017 conference in Prague (Czech Republic) this week.Do not miss Synthelis CSO Sandra Cortez's presentation "Cell-free expression as a new alternative for difficult-to express-proteins" on Thursday, June 15 at 1.55 pm.During the event, meet our President Bruno Tillier and CSO Sandra Cortez to discuss your projects and see how our cell-free technology could [...]
Synthelis will be at the NISB 2017 (Neutrons In Structural Biology) in Grenoble (France) this week. Synthelis cell-free technology will be featured in a presentation by Thomas Soranzo from Université Grenoble-Alpes (June 8th at 11:05 am) on cell-free protein synthesis. Feel free to arrange a meeting by contacting us. Learn more about the NISB 2017.
Synthelis will be at the 4th NovAliX conference in Strasbourg (France) in 2 weeks.Many opportunities to meet with us at the event: - At booth #6- During our presentation: "Cell-free technology, expertise and services for your project in structural biology", on Tuesday June 6th at 5:15pm (session 1: Biophysical Techniques for the Study of Integral Membrane Proteins)- During the poster [...]
A new transcriptional regulator is now available in our protein catalog. AROS is a direct active regulator of SIRT1, an NAD+-dependent deacetylase. Depletion of AROS enhances p21 expression and increases both the G0/G1 population and apoptosis in response to DNA damage, whereas AROS overexpression improves cell survival. AROS is available in soluble format. Feel free to contact our in-house [...]
Synthelis will be at the 17e journée scientifique de l'IMBL, Glycosciences et Lipidomique. Do not miss our poster presentation "New tethered phospholipid bilayers integrating a functional transmembrane protein for the development of a biochip dedicated to ligand binding studies"? Request a copy at email@example.com Feel free to arrange a meeting by contacting us. For more information, visit the event page.
Synthelis has been selected to present during the “Difficult to Express Proteins” session at PEGS Boston 20172 May 2017
Do not miss Synthelis' presentation today at 9:30am during the "Expression stream", focus on "Difficult to Express Proteins"session. To arrange a meeting with our sales manager Safia Ezzine, meet us directly during our presentation, at poster A109 or by emilai us at firstname.lastname@example.org.
Synthelis will be at the Protein Engineering Summit: PEGS Boston 2017. Meet us at poster #A109, during the Poster Session 4A: "Difficult to express proteins" at our poster "Cell-Free Expression as a New Alternative for Difficult-to-Express Proteins" (01/05 at 3:20pm and 5:40pm / 02/05 at 10:00am, 1:20pm and 3:35pm). Feel free to arrange a meeting by contacting us. [...]
Synthelis is pleased to announce that its protein catalog is now available on the life science product platform Biocompare.Access the full list here.
NEW Application Note from Synthelis! “Label-free Kinetic Analysis of Membrane Protein Interactions Using Biolayer Interferometry (BLI)”18 April 2017
In this application note, Synthelis demonstrates the determination of interaction between a liposome embedded GPCR protein and specific ligands using the Octet RED96 system (Pall FortéBio). The biolayer interferometry (BLI) monitors the binding of proteoliposomes to their partners directly in real time to measure physiologically-relevant results closely to native conditions. Synthelis proteoliposomes are therefore adapted [...]
Meet us next week at the Cambridge Ion Channel Forum at Medimmune offices in Cambridge, UK.Feel free to arrange a meeting by contacting us. Our sales manager Safia Ezzine will then be attending the 10th Annual Proteins & Antibodies Congress (24-25 April) in London, so let us know when is the best time to meet. For more information, visit [...]
We are looking for a project manager for our headquarters in Grenoble, France. Join us now!See job description. Do no hesitate to contact us at email@example.com.
Synthelis has been invited to conduct a seminar today at Hôpital Cochin, Paris, France. The seminar will focus on how cell-free system can bring new solutions for the protein production. Sandra Cortès, PhD, Synthelis CSO will then present "Systèmes d’expression « cell-free »: de nouvelles possibilités pour la production de protéines" Please note that this seminar is [...]
A new receptor is now available in our protein catalog. The major membrane protein F5L is a Variola virus protein required for the virus replication. The other potential functions of this protein are still unknown. Feel free to contact our in-house experts to learn more and discuss how this protein could be relevant to your application. Learn more about F5L. Are [...]
Synthelis will attend the Forum de la Recherche en Cancérologie Auvergne-Rhône-Alpes, 4-5 April 2017, Villeurbanne29 March 2017
Meet us next week at the Forum de la Recherche en Cancérologie Auvergne-Rhône-Alpes in Villeurbanne (France)Feel free to arrange a meeting by contacting us. For more information, visit the event page.
Meet us in London, UK, at the 10th Annual Proteins & Antibodies Congress!Visit our poster "Cell-free expression as an innovative tool for antigen production" (poster number to be announced shortly) and learn more about how our cell-free technology can support you in your projects.Feel free to arrange a meeting by contacting us. Our sales manager Safia Ezzine will [...]
We are looking for a lab technician for our headquarters in Grenoble, France. Join us now!See job description. Do no hesitate to contact us at firstname.lastname@example.org.
NEW publication! “Therapeutic effects of proteoliposomes on X-linked chronic granulomatous disease: proof of concept using macrophages differentiated from patient-specific induced pluripotent stem cells”22 March 2017
Synthelis’ innovative patented cell-free technology allows customized expression and characterization of active proteins, packaged in proteoliposomes or delivered in a detergent solution. This makes it particularly suitable for the expression of membrane proteins, which are well known to be challenging to produce in a usable form. The independence of cell-free technology from the physiological constraints of cell-based systems, [...]
Synthelis is featured in this week issue of Dauphiné Entreprises journal. The article highlights our new distributor agreement with Japanese company Funakoshi Co., Ltd. Funakoshi has then become the first distributor of Synthelis off-the-shelf products in Japan, extending our cell-free technology offer more globally. Our President Bruno Tillier explains this strategic partnership as well latest news at Synthelis. Read the [...]